Peptides for Libido: Evidence-Based Options for Sexual Health

Low libido is one of the most common sexual health complaints in both men and women. Estimates suggest that hypoactive sexual desire disorder (HSDD) affects roughly 10% of women and a significant percentage of men, yet treatment options have historically been limited, particularly for desire-based dysfunction as opposed to performance-based issues [1]. Medications like sildenafil (Viagra) and tadalafil (Cialis) address blood flow, but they do nothing for someone who simply has no interest in sex.

This is where peptide therapy has introduced a genuinely new mechanism. PT-141 (bremelanotide), marketed as Vyleesi, is the first and only FDA-approved treatment that works on sexual desire through the central nervous system rather than the vascular system. It represents a fundamentally different approach, targeting the brain’s motivational circuitry rather than the mechanics of arousal.

Beyond PT-141, several other peptides have shown effects on sexual function through various pathways: kisspeptin through reproductive hormone signaling, oxytocin through bonding and arousal, and melanotan II as the broader-acting predecessor to PT-141. Here’s what the evidence supports and where the science still has gaps.

Key takeaways

• PT-141 (bremelanotide/Vyleesi) is the only FDA-approved peptide for sexual desire. It works in the brain, not on blood flow
• PT-141 works for both men and women, though FDA approval is currently only for premenopausal women with HSDD
• Kisspeptin shows promise for improving sexual desire through GnRH and reproductive hormone optimization
• Melanotan II was the original discovery that led to PT-141, but carries more side effects and safety concerns
• Oxytocin may enhance arousal and emotional bonding but has limited standalone evidence for libido

Table of contents

1. Why desire is different from arousal
2. PT-141 (bremelanotide): the FDA-approved option
3. Kisspeptin: hormonal pathway to desire
4. Oxytocin: bonding, arousal, and context
5. Melanotan II: the predecessor with caveats
6. Comparing peptides for libido
7. Peptides for libido in men vs. women
8. Safety and side effects
9. FAQ
10. Sources

Why desire is different from arousal

Most conventional treatments for sexual dysfunction target the arousal phase: the physical mechanics of increased blood flow, lubrication, or erection. Sildenafil and tadalafil are PDE5 inhibitors that relax smooth muscle in blood vessels. They work well for erectile dysfunction caused by vascular issues, but they don’t create desire. A person can have a perfectly functional physical response and still have zero interest in sex.

Sexual desire (the motivational drive to seek out and engage in sexual activity) is mediated by the central nervous system. It involves dopaminergic pathways, melanocortin receptors in the hypothalamus, and a complex interplay of hormones including estrogen, testosterone, and neuropeptides [2]. When desire is the problem, vascular medications miss the target entirely.

This distinction matters because HSDD is primarily a disorder of desire, not arousal. Patients with HSDD have diminished or absent sexual fantasies and desire for sexual activity, causing significant personal distress. Until PT-141 and flibanserin (Addyi) came along, there was no pharmacological treatment that directly addressed this central nervous system component.

Peptides that work on melanocortin receptors, GnRH signaling, or oxytocin pathways offer a way to modulate the brain circuits involved in desire, which is why they represent a genuinely different category of treatment.

PT-141 (bremelanotide): the FDA-approved option

PT-141, sold under the brand name Vyleesi, is the standout peptide in the sexual health space. It was approved by the FDA in June 2019 for the treatment of HSDD in premenopausal women, making it the first injectable treatment and the first melanocortin-based therapy approved for this indication [3].

The accidental discovery

PT-141’s origin story is one of the more interesting in pharmaceutical development. Researchers studying melanotan II (a synthetic peptide designed to stimulate tanning without UV exposure) noticed that male test subjects were developing spontaneous erections as a side effect. This observation led to the isolation of the specific melanocortin receptor activity responsible for the sexual effects, resulting in a more targeted molecule: bremelanotide (PT-141) [4].

Unlike melanotan II, PT-141 was engineered to primarily activate melanocortin-4 receptors (MC4R) in the hypothalamus, the brain region governing sexual motivation. This selectivity reduced the tanning, appetite suppression, and other off-target effects seen with melanotan II while preserving the pro-sexual activity.

Mechanism of action

PT-141 activates melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the central nervous system. These receptors are part of the hypothalamic circuitry that regulates sexual arousal, desire, and motivation [5]. When activated, they modulate dopaminergic signaling in brain regions associated with reward and motivation, essentially increasing the neurological “drive” toward sexual behavior.

This is fundamentally different from how PDE5 inhibitors work. PT-141 doesn’t increase blood flow to the genitals. It doesn’t require physical stimulation to take effect. It acts upstream, on the brain circuits that generate the desire for sexual activity in the first place.

Clinical evidence

The FDA approval for Vyleesi was based on two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT studies) involving over 1,200 premenopausal women with HSDD [6].

Key findings from the RECONNECT trials:

• Desire scores improved significantly compared to placebo, measured by the Female Sexual Function Index (FSFI) desire domain
• Arousal and orgasm scores also improved, suggesting downstream benefits from increased desire
• Distress scores decreased significantly, with patients feeling less bothered by their low desire
• 25% of PT-141 patients reported a meaningful increase in desire compared to 17% on placebo
• Effects were observed within the first month of treatment

Subgroup analyses from the RECONNECT Phase 3 studies provided additional detail on which patient populations responded best to bremelanotide [16]. A full safety review across all bremelanotide clinical development programs confirmed the drug’s overall tolerability profile, with nausea as the most common adverse event [17].

The clinical protocol is 1.75 mg administered by subcutaneous injection in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. It is not taken daily, only on an as-needed basis, with a maximum of one dose per 24 hours and no more than 8 doses per month [3].

For a detailed look at PT-141 in female patients, see our guide on PT-141 for women.

PT-141 in men

While the FDA approval is for women, PT-141 has been studied in men as well. Early Phase 2 trials in men with erectile dysfunction showed that PT-141 produced erections in a dose-dependent manner, including in men who had failed to respond to sildenafil [7]. The effect was notable because it suggested PT-141 could work through a completely different mechanism than existing ED treatments.

However, the development program for PT-141 in men was paused after concerns about blood pressure effects at higher doses. The compound was ultimately brought to market for women only. In clinical practice, some physicians prescribe PT-141 off-label for men, particularly those with desire-based sexual dysfunction rather than purely vascular ED. For more on peptide options in male patients, see our guide on peptides for men.

Kisspeptin: hormonal pathway to desire

Kisspeptin is a naturally occurring neuropeptide encoded by the KISS1 gene. It plays a central role in reproductive biology by stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn drives the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [8].

How kisspeptin affects sexual function

Kisspeptin’s connection to libido is twofold. First, by stimulating GnRH and downstream sex hormones (testosterone in men, estrogen and progesterone in women), it can address desire problems rooted in hormonal deficiency. Second, and more intriguingly, kisspeptin appears to have direct effects on brain circuits involved in sexual arousal that go beyond simple hormone optimization.

A 2017 study published in The Journal of Clinical Investigation used functional MRI to demonstrate that kisspeptin-54 administration enhanced brain activity in regions associated with sexual arousal when subjects viewed erotic images [9]. The effect was observed in the posterior cingulate cortex and other limbic structures — areas involved in processing sexual stimuli and generating motivated behavior.

The evidence so far

Research on kisspeptin for sexual health is still in early clinical stages, but the data is promising:

• Healthy men given kisspeptin-54 showed increased LH pulsatility and enhanced brain activation in response to sexual stimuli [9]
• Men with functional hypogonadism (low testosterone without structural pituitary disease) showed restored reproductive hormone levels with kisspeptin administration [10]
• Women in early studies showed modulated LH secretion patterns, though sexual function endpoints have been less extensively studied

The limitation is that kisspeptin research remains primarily academic. There are no FDA-approved kisspeptin products, and it is not yet widely available through compounding pharmacies. The peptide also has a short half-life, which presents practical challenges for therapeutic use. Longer-acting analogs are in development.

Oxytocin: bonding, arousal, and context

Oxytocin, sometimes called the “bonding hormone,” is released during physical intimacy, orgasm, and social connection. Its role in sexual function has been studied for decades, though its effects on libido specifically are more complex than often presented.

What oxytocin does

Oxytocin enhances the subjective experience of arousal and orgasm rather than driving desire from scratch. Studies have shown that intranasal oxytocin can increase genital arousal in women, enhance the intensity of orgasm in both sexes, and promote feelings of emotional closeness during sexual activity [11]. It operates primarily through modulation of the autonomic nervous system and limbic circuitry.

A 2012 study found that intranasal oxytocin improved sexual function in men with sexual dysfunction, particularly in the domains of arousal and orgasm satisfaction [12]. The effects were modest but statistically significant.

A note on effect sizes

Independent analyses have raised questions about the clinical significance of bremelanotide’s effects. A 2024 critical analysis in the Journal of Sex Research described the effect sizes as “small” and questioned whether the outcomes meet meaningful clinical thresholds [15]. Similarly, a 2021 commentary in the Drug and Therapeutics Bulletin argued that the regulatory approval of both bremelanotide and flibanserin set a concerning precedent given the modest efficacy demonstrated in trials [18]. These perspectives are important for setting realistic expectations about what PT-141 can achieve.

Limitations for libido

Oxytocin’s weakness as a standalone libido treatment is that it works better as an enhancer than an initiator. It can make an existing sexual encounter more satisfying, but it doesn’t generate the desire to seek one out. For someone with HSDD, oxytocin alone is unlikely to be sufficient.

That said, some peptide therapy for women protocols incorporate oxytocin alongside other interventions: hormone optimization, PT-141 for desire, and oxytocin for the arousal and satisfaction components. This layered approach reflects the complexity of female sexual response.

Melanotan II: the predecessor with caveats

Melanotan II is the peptide that started the entire melanocortin approach to sexual health. Developed at the University of Arizona in the 1990s as a tanning agent, it was during early testing that researchers observed its potent effects on sexual arousal [4]. PT-141 was derived from melanotan II to isolate the sexual function benefits from the other effects.

How it works

Melanotan II is a non-selective melanocortin receptor agonist. It activates MC1R (pigmentation), MC3R and MC4R (sexual function and appetite), and MC5R (exocrine function) [13]. This broad receptor activity is why it produces multiple effects simultaneously: skin darkening, appetite suppression, and increased libido.

The pro-sexual effects of melanotan II are well-documented in early clinical studies. Both men and women reported increased sexual desire and spontaneous arousal during tanning studies. In men, melanotan II produced erections without sexual stimulation — an effect strong enough to be clinically notable [4].

Why PT-141 is preferred

Despite its efficacy for libido, melanotan II carries significant concerns that led researchers to develop PT-141 as a more targeted alternative:

• Unregulated skin darkening. Melanogenesis is not always uniform, and melanotan II can cause darkening of moles and nevi, which complicates skin cancer screening [14]
• Nausea and facial flushing, more common and more severe than with PT-141
• Appetite suppression, which may be unwanted in many patients
• Blood pressure effects, more pronounced than with PT-141 due to broader receptor activation
• No FDA approval. Melanotan II has never been approved by any regulatory agency
• Unregulated supply. Most melanotan II is sourced from gray-market suppliers with inconsistent quality and purity

Several case reports have documented adverse events with melanotan II, including severe nausea, atypical mole changes, and in rare cases, rhabdomyolysis [14]. The Australian TGA and other regulatory bodies have issued specific warnings against its use.

For these reasons, clinicians who treat sexual dysfunction with melanocortin-based peptides strongly favor PT-141 over melanotan II. The narrower receptor profile of PT-141 preserves the libido benefits while substantially reducing the risk profile.

Comparing peptides for libido

Peptide	Primary Mechanism	FDA Status	Evidence Level	Best For
PT-141 (Bremelanotide)	MC3R/MC4R agonist (brain)	FDA-approved (Vyleesi)	Phase 3 trials	Desire-based dysfunction
Kisspeptin	GnRH stimulation	Investigational	Phase 1/2 trials	Hormonal optimization
Oxytocin	Autonomic/limbic modulation	FDA-approved (other uses)	Mixed clinical data	Arousal/satisfaction enhancement
Melanotan II	Non-selective MCR agonist	Not approved	Early clinical + case reports	Not recommended due to safety

Peptides for libido in men vs. women

Sexual dysfunction presents differently by sex, and peptide approaches reflect this.

Women

Female sexual desire is influenced by hormonal cycles, psychological factors, relationship context, and neurochemistry. PT-141 is particularly relevant for women because HSDD is more prevalent in women and because existing treatments (hormone therapy, flibanserin) have significant limitations. The FDA specifically approved Vyleesi for premenopausal women with generalized, acquired HSDD, meaning the low desire developed over time rather than being lifelong, and occurs regardless of partner or situation [3].

Kisspeptin may also be relevant for women approaching perimenopause, where declining reproductive hormones contribute to reduced desire. Oxytocin protocols are sometimes used to enhance arousal in women who have adequate desire but difficulty with physical response.

Men

Men with libido issues often have overlapping desire and arousal components. PT-141 can address the desire component in men, particularly those whose ED has a psychological or neurological basis rather than a vascular one. For men with low testosterone driving their low libido, kisspeptin offers a way to stimulate endogenous testosterone production without exogenous testosterone replacement, potentially preserving fertility, which TRT can compromise [10].

Some practitioners combine PT-141 with PDE5 inhibitors for men who have both desire and vascular components to their dysfunction. This addresses both the central and peripheral mechanisms simultaneously.

Safety and side effects

PT-141

The most common side effects from the RECONNECT trials were nausea (40% vs. 1% placebo), flushing (20%), injection site reactions (13%), and headache (11%) [3]. Nausea is typically transient, peaking 1-2 hours after injection and resolving within a few hours. It tends to diminish with repeated use.

PT-141 can cause a transient increase in blood pressure, which is why it carries a precaution for patients with uncontrolled hypertension or cardiovascular disease. Skin hyperpigmentation has been reported in about 1% of patients, particularly at injection sites and on the face and gums. For a detailed breakdown, see our guide on PT-141 side effects.

Kisspeptin

Kisspeptin has shown a favorable safety profile in clinical studies, with no serious adverse events reported. Common effects include warmth or flushing at the injection site. Long-term safety data is limited since most studies have been short-duration academic protocols [8].

Oxytocin

Intranasal oxytocin is generally well tolerated. Side effects can include nasal irritation, headache, and in rare cases, uterine contractions (it is the same molecule used to induce labor, though intranasal doses are far lower). It should be used with caution in pregnant women [11].

Melanotan II

Melanotan II has the highest risk profile of the peptides discussed here. Beyond the nausea and flushing common to melanocortin agonists, it carries risks of uncontrolled melanogenesis, mole changes that can mimic melanoma, and cardiovascular effects. It is not recommended by any medical regulatory body and should be avoided in favor of PT-141 [14].

FAQ

What is the best peptide for libido?▼

PT-141 (bremelanotide) has the strongest evidence and is the only FDA-approved peptide for sexual desire. It works through melanocortin receptors in the brain to increase desire, arousal, and satisfaction. For people with hormonal contributors to low libido, kisspeptin may also be worth discussing with a healthcare provider, though it remains investigational.

Does PT-141 work for both men and women?▼

Yes. Clinical studies have demonstrated pro-sexual effects in both sexes. The FDA approval (as Vyleesi) is specifically for premenopausal women with HSDD, but PT-141 has shown efficacy in men with erectile dysfunction in Phase 2 trials, and some physicians prescribe it off-label for male patients with desire-based sexual dysfunction.

How quickly does PT-141 work?▼

PT-141 is administered by subcutaneous injection at least 45 minutes before anticipated sexual activity. Most patients report effects beginning within 30-60 minutes, with peak effects occurring 1-2 hours after injection. The effects can last 6-12 hours, though individual responses vary.

Is melanotan II safe for improving libido?▼

Melanotan II is not recommended. While it does have pro-sexual effects, it has never been approved by any regulatory agency, carries significant side effects including uncontrolled skin darkening and mole changes, and is typically sourced from unregulated suppliers. PT-141 was specifically developed to provide the libido benefits of melanotan II with a better safety profile and is the preferred option.

Can peptides replace hormone therapy for low libido?▼

It depends on the cause. If low libido is driven primarily by hormonal deficiency (low testosterone in men or declining estrogen in perimenopausal women), then hormone optimization remains a foundational treatment. Peptides like PT-141 work through a different mechanism (melanocortin receptors) and can be effective even when hormones are normal. In practice, some patients benefit from combining hormone therapy with PT-141 for a combined approach.

Do I need a prescription for PT-141?▼

Yes. PT-141 (Vyleesi) is a prescription medication. It can be obtained through a prescribing physician or through a licensed peptide therapy clinic that offers telehealth consultations. A medical evaluation is necessary to confirm the diagnosis and rule out contraindications such as uncontrolled hypertension.

Sources

1. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978. doi:10.1097/AOG.0b013e3181898cdb

2. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506-1533. doi:10.1111/j.1743-6109.2009.01309.x

3. U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release. June 21, 2019. Accessed March 2026.

4. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

5. Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-10204. doi:10.1073/pnas.0404196101

6. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500

7. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2006;18(2):135-141. doi:10.1038/sj.ijir.3901396

8. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. doi:10.1093/humupd/dmu009

9. Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. doi:10.1172/JCI89519

10. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. doi:10.1172/JCI75730

11. Behnia B, Heinrichs M, Bergmann W, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav. 2014;65(3):308-318. doi:10.1016/j.yhbeh.2014.01.009

12. Burri A, Heinrichs M, Schedlowski M, Kruger TH. The acute effects of intranasal oxytocin administration on endocrine and sexual function in males. Psychoneuroendocrinology. 2008;33(5):591-600. doi:10.1016/j.psyneuen.2008.01.014

13. Haskell-Luevano C, Hadley ME. Discovery and characterization of the melanocortin receptor subtypes. Ann N Y Acad Sci. 1999;885:153-167. doi:10.1111/j.1749-6632.1999.tb08672.x

14. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. doi:10.1159/000356389

15. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024. PubMed

16. Subgroup Analyses from RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health. 2022. PubMed

17. Safety Profile of Bremelanotide Across Clinical Development. J Womens Health. 2022. PubMed

18. Bremelanotide and flibanserin for low sexual desire: the fallacy of regulatory precedent. Drug Ther Bull. 2021. PubMed